Evidence map›Paper›PMID 38315685›Full record

ArticlePloS one2024

Perinatal choline supplementation prevents learning and memory deficits and reduces brain amyloid Aβ42 deposition in AppNL-G-F Alzheimer's disease model mice.

Thomas A Bellio, Jessenia Y Laguna-Torres, Mary S Campion, Jay Chou, Sheila Yee, Jan K Blusztajn, Tiffany J Mellott

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Thomas A BellioDepartment of Pathology & Laboratory Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States of America.ORCID 0009-0007-7807-6848
Jessenia Y Laguna-TorresDepartment of Pathology & Laboratory Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States of America.
Mary S CampionDepartment of Pathology & Laboratory Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States of America.
Jay ChouDepartment of Pathology & Laboratory Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States of America.
Sheila YeeDepartment of Pathology & Laboratory Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States of America.ORCID 0000-0002-5221-5957
Jan K BlusztajnDepartment of Pathology & Laboratory Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States of America.
Tiffany J MellottDepartment of Pathology & Laboratory Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States of America.ORCID 0000-0003-3287-9374

Funding

Age-Associated Lipidomic Changes in Alzheimer's DiseaseRF1AG057768 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BLUSZTAJN, JAN KRZYSZTOF, STEIN, THOR · 2019 to 2021
$4.5M
MicroRNAs as Diagnostic and Prognostic Biomarker of Alzheimer's DiseaseRF1AG078299 · NIA · RHODE ISLAND HOSPITAL · PI BLUSZTAJN, JAN KRZYSZTOF, DELALLE, IVANA · 2022 to 2022
$2.4M
BMP9 as a juvenile protective factor in cognitive agingR01AG045031 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BLUSZTAJN, JAN KRZYSZTOF · 2014 to 2018
$1.8M
Therapeutic Effects of Dietary Choline Mediated by IGF2 in AD Mouse ModelR21AG056901 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI MELLOTT, TIFFANY J. · 2018 to 2019
$454k
NIA NIH HHS R01 AG045031NIA NIH HHS R21 AG056901NIA NIH HHS RF1 AG057768NIA NIH HHS RF1 AG078299
6 · The paper itself

Abstract

Alzheimer's disease (AD) is characterized by cognitive and memory impairments and neuropathological abnormalities. AD has no cure, inadequate treatment options, and a limited understanding of possible prevention measures. Previous studies have demonstrated that AD model mice that received a diet high in the essential nutrient choline had reduced amyloidosis, cholinergic deficits, and gliosis, and increased neurogenesis. In this study, we investigated the lifelong effects of perinatal choline supplementation on behavior, cognitive function, and amyloidosis in AppNL-G-F AD model mice. Pregnant and lactating mice were given a diet containing either 1.1 g/kg (control) or 5 g/kg (supplemented) of choline chloride until weaning and subsequently, all offspring received the control diet throughout their life. At 3, 6, 9, and 12 months of age, animals were behaviorally tested in the Open Field Test, Elevated Plus Maze, Barnes Maze, and in a contextual fear conditioning paradigm. Immunohistochemical analysis of Aβ42 was also conducted on the brains of these mice. AppNL-G-F mice displayed hippocampal-dependent spatial learning deficits starting at 3-months-old that persisted until 12-months-old. These spatial learning deficits were fully prevented by perinatal choline supplementation at young ages (3 and 6 months) but not in older mice (12 months). AppNL-G-F mice also had impaired fearful learning and memory at 9- and 12-months-old that were diminished by choline supplementation. Perinatal choline supplementation reduced Aβ42 deposition in the amygdala, cortex, and hippocampus of AppNL-G-F mice. Together, these results demonstrate that perinatal choline supplementation is capable of preventing cognitive deficits and dampening amyloidosis in AppNL-G-F mice and suggest that ensuring adequate choline consumption during early life may be a valuable method to prevent or reduce AD dementia and neuropathology.

Indexed as

Alzheimer DiseaseAmyloidosisAmyloid beta-PeptidesAnimalsBrainCholineDietary SupplementsDisease Models, AnimalFemaleLactationMaze LearningMemory DisordersMiceMice, TransgenicPregnancyAmyloid beta-PeptidesCholine

Identifiers

PMID38315685
PMCPMC10843108

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.